Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Theraclion

Market Cap 4.99Cr 5.68Cr 4.59Cr 4.3Cr 8.06Cr 537.64Cr 8.19Cr 55Cr 21Cr 263.79Cr 21Cr 21Cr 916.85Cr P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 5.77Cr 6.57Cr 5.32Cr 4.98Cr 9.33Cr 622.31Cr 9.48Cr 64Cr 25Cr 305.34Cr 25Cr 24Cr 1.06TCr EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
54.37%
Yield 2024 *
-
Yield 2025 -
1 day+66.25%
3 months+66.25%
6 months+66.25%
Current year+66.25%
Current year 0.53
Extreme 0.532
0.53
1 year 0.53
Extreme 0.532
0.53
3 years 0
Extreme 0.0002
0.59
5 years 0
Extreme 0.0002
2.28
10 years 0
Extreme 0.0002
2.6
Manager TitleAgeSince
Chief Executive Officer - 24/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 01/02/2018
Director/Board Member - 13/02/2019
Director/Board Member - 13/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+66.25%-.--% - - 5.43Cr
+1.15%-0.69%+17.28%-10.47% 17TCr
+0.06%-3.33%-21.73%+23.20% 14TCr
+0.44%-1.31%-8.85%-24.86% 13TCr
+2.86%-2.81%-55.45%-15.51% 6.59TCr
+1.25%-1.84%+15.44%-3.75% 4.94TCr
+0.06%-2.21%-25.84%-32.63% 4.41TCr
+0.14%-1.30%+9.08%+6.07% 3.57TCr
-0.29%-0.93%+4.19%+37.47% 3.52TCr
+5.08%+0.77%-10.46%-20.17% 2.76TCr
Average +7.29%-1.60%-8.48%-4.52% 7.77TCr
Weighted average by Cap. +0.55%-1.98%-7.27%-4.71%

Financials

2024 2025
Net sales 8L 9L 8L 7L 13.42L 8.95Cr 13.64L 91.86L 35.56L 4.39Cr 35.48L 34.71L 15Cr 7L 7L 6L 6L 10.54L 7.03Cr 10.71L 72.14L 27.92L 3.45Cr 27.86L 27.26L 12Cr
Net income -57.57L -65.53L -53.05L -49.66L -93.04L -62Cr -94.61L -6.37Cr -2.47Cr -30Cr -2.46Cr -2.41Cr -105.86Cr -56.9L -64.77L -52.43L -49.08L -91.96L -61Cr -93.51L -6.3Cr -2.44Cr -30Cr -2.43Cr -2.38Cr -104.63Cr
Net Debt 34.11L 38.82L 31.43L 29.42L 55.12L 37Cr 56.05L 3.77Cr 1.46Cr 18Cr 1.46Cr 1.43Cr 63Cr 78.52L 89.38L 72.35L 67.73L 1.27Cr 85Cr 1.29Cr 8.69Cr 3.36Cr 42Cr 3.36Cr 3.28Cr 144.39Cr
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!